FDA Class II Recall Targets 3,744 Bottles of Generic Blood Pressure Meds for Dissolution Failures

3 min read
Source: NBC 5 Chicago
FDA Class II Recall Targets 3,744 Bottles of Generic Blood Pressure Meds for Dissolution Failures
Photo: NBC 5 Chicago
TL;DR

The FDA has classified a voluntary recall of 3,744 bottles of generic blood pressure medication as Class II. Initiated by Macleods Pharma USA on October 7, the recall targets specific lots of olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets that failed dissolution testing. While the risk of serious harm is considered remote, patients are advised to check their lot numbers and consult their doctors before discontinuing use.

Key points

  • Macleods Pharma USA initiated a voluntary recall on October 7 for 3,528 30-count and 216 90-count bottles of olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets.
  • The FDA classified the recall as Class II on October 26, indicating that use of the affected medication may cause temporary or medically reversible adverse health consequences, but serious harm is unlikely.
  • The recall was triggered by 'failed dissolution specifications,' meaning the pills did not break down or release active ingredients at the required rate, potentially rendering them ineffective for treating high blood pressure.
  • Affected lots include NDC 33342-246-07 (30-count) and NDC 33342-246-10 (90-count), both with an expiration date of May 31, 2027.
  • The FDA did not issue specific consumer instructions, but experts advise patients to contact their healthcare providers before stopping the medication, as the brand-name version Tribenzor is not recalled.

Background

This recall follows a similar September incident involving 13,567 bottles of chlorthalidone tablets from Inventia Healthcare Ltd., which were also pulled for failing dissolution testing. The current recall affects a generic version of the brand-name drug Tribenzor, which is not included in the recall. Previous coverage from our archive confirms the FDA’s Class II designation and the specific lot numbers involved, emphasizing the need for patients to verify their medication details.

How outlets are covering it

All four sources (NBC Chicago, Fox Business, Prevention, and USA Today) agree on the core facts: the recall involves 3,744 bottles of Macleods Pharma’s generic blood pressure medication, initiated on October 7 and classified as Class II by the FDA on October 26. The primary reason cited is 'failed dissolution specifications.' NBC Chicago and Fox Business highlight the nationwide scope and the specific lot numbers. Prevention and USA Today emphasize the consumer action, advising patients to check their labels and consult doctors before discontinuing use. USA Today notes that the brand-name Tribenzor is not recalled, while Fox Business mentions a prior recall of a different blood pressure medication. No significant disagreements were found among the outlets.

Why it matters

The recall affects a common medication used to treat hypertension, a condition that affects millions of Americans. While the Class II designation suggests low risk of serious harm, the failure of dissolution specifications could mean the medication is ineffective, potentially leaving patients with uncontrolled blood pressure. Patients are urged to verify their lot numbers and consult healthcare providers to ensure they are receiving effective treatment.

What to watch

The recall remains ongoing, and the FDA has not issued specific instructions for consumers. Patients with the affected lots should contact their healthcare providers for guidance on whether to continue taking the medication or switch to an alternative. Macleods Pharma USA has not responded to requests for comment from NBC Chicago and Fox Business.

Share this article

Want the full story? Read the original reporting

Read on NBC 5 Chicago